Bristol-Myers Squibb | BMY - Operating Expenses


Bristol-Myers Squibb reported $23.4B in Operating Expenses for its fiscal quarter ending in September of 2026.





Operating Expenses Change Date
AbbVie USD 10.52B 258M Sep/2026
Abbott USD 11.66B 1.2B Sep/2026
ALKERMES USD 1.86B 56.17M Sep/2026
Amgen USD 5.69B 6B Sep/2026
AstraZeneca USD 11.55B 674M Sep/2026
Biogen USD 2.32B 663.6M Sep/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Coherus Biosciences USD 51.83M 2.48M Dec/2025
Drreddys Laboratories INR 73.9B 431M Sep/2026
Eli Lilly USD 10.52B 496M Jun/2026
Gilead Sciences USD 13.04B 9.09B Sep/2026
GlaxoSmithKline GBP 6.03B 227M Sep/2026
J&J USD 18.93B 1.09B Sep/2026
Medtronic USD 7.92B 203M Jun/2026
Merck USD 10.75B 5.02B Sep/2026
Novartis USD 9.88B 325M Sep/2026
Novo Nordisk DKK 44.73B 7.52B Jun/2026
Perrigo USD 961.4M 670.9M Sep/2026
Pfizer USD 89B 3.81B Sep/2026
Phibro Animal Health USD 417.67M 1.04B Sep/2026
Prestige Brands USD 213.19M 7.06M Jun/2026
Regeneron Pharmaceuticals USD 33.5B 1.79B Sep/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sanofi EUR 10.51B 598M Sep/2026
Sanofi EUR 9.92B 941M Jun/2026
United Therapeutics USD 6.28B 124.3M Sep/2026
Zoetis USD 3.3B 155M Sep/2026